Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to add Halda’s precision oncology assets to its pipeline. The deal centers on HLD-0915, a clinical-stage prostate cancer candidate that produced notable PSA responses in a Phase I/II cohort, and Halda’s regulatorily enabled RIPTAC platform for tumor-selective heterobifunctional molecules. John C. Reed, J&J EVP of Innovative Medicine R&D, said the data and safety profile underpin the strategic rationale. The acquisition gives J&J immediate clinical-stage exposure paired with a platform designed to generate tumor-selective small-molecule modalities.